Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Sales and Divestitures (2016 - 2023)

Editas Medicine (EDIT) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $210701.0 as the latest value for Q2 2023.

  • On a quarterly basis, Gains from Sales and Divestitures fell 9.46% to $210701.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $210701.0, a 9.46% decrease, with the full-year FY2022 number at $286642.0, up 7.25% from a year prior.
  • Gains from Sales and Divestitures was $210701.0 for Q2 2023 at Editas Medicine, up from $146209.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $304638.0 in Q4 2020 to a low of $18000.0 in Q1 2019.
  • A 5-year average of $179748.3 and a median of $200888.0 in 2021 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 82.7% in 2019, then soared 1085.52% in 2020.
  • Editas Medicine's Gains from Sales and Divestitures stood at $99919.0 in 2019, then surged by 204.88% to $304638.0 in 2020, then decreased by 12.27% to $267268.0 in 2021, then grew by 7.25% to $286642.0 in 2022, then fell by 26.49% to $210701.0 in 2023.
  • Per Business Quant, the three most recent readings for EDIT's Gains from Sales and Divestitures are $210701.0 (Q2 2023), $146209.0 (Q1 2023), and $286642.0 (Q4 2022).